BBIO BridgeBio Pharma, Inc.
FY2025 10-K
BridgeBio Pharma, Inc. (BBIO) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
- • New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
Management Discussion & Analysis
- • No revenue figures or YoY changes disclosed in provided text
- • No profitability or margin percentages reported
Risk Factors
- • Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
- • Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
Financial SummaryXBRL
Revenue
$502M
Net Income
-$725M
Operating Margin
-104.2%
Net Margin
-144.4%
ROE
34.7%
Total Assets
$936M
EPS (Diluted)
$-3.78
Operating Cash Flow
-$446M
Source: XBRL data from BridgeBio Pharma, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BridgeBio Pharma, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.